Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Vomiting 2Nausea 2

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × casopitant × Clear all
NCT00334646 2017-11-17

Cyclophosphamide Drug Interaction Study In Cancer Patients

GlaxoSmithKline

Phase 1 Terminated
25 enrolled

Nausea, Vomiting

NCT00440128 2017-08-04

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

GlaxoSmithKline

Phase 1 Completed
12 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡